A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Single‐Dose and Multiple‐Rising‐Dose Study of the BTK Inhibitor TAK‐020 in Healthy Subjects

Bruton’s tyrosine kinase (BTK) is a target for treatment of hematologic malignancies and autoimmune diseases. TAK‐020 is a highly selective covalent BTK inhibitor that inhibits both B cell receptor and fragment crystallizable receptor signaling. We assessed the safety/tolerability and pharmacokineti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Transl Sci
Hlavní autoři: Esfandiari, Ehsanollah, Chen, Mary, Smithson, Glennda, Blair, Derek, Faessel, Helene, Wagner, John, Mclean, Lachy, Fedyk, Eric R.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2021
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8212709/
https://ncbi.nlm.nih.gov/pubmed/33650758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12871
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky